Ocugen’s Gene Therapy Trials Light Up Times Square—New Data Offers Hope for Rare Retinal Diseases
Ocugen’s Gene Therapy Trials Light Up Times Square—New Data Offers Hope for Rare Retinal Diseases
Novo Nordisk’s oral obesity drug shows superior efficacy over Eli Lilly’s candidate, reshaping the competitive landscape in metabolic …
Facing partnership setbacks and pipeline pressure, Editas Medicine lays off 65% of its staff and pivots toward its …
With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping …
Despite a muted IPO market and cautious M&A activity, biotech in 2024 proved that innovation never sleeps—especially when …
Clinical research in 2024 is progressing rapidly, driven by pioneering studies, technological innovation, and evolving regulatory frameworks that …
Clinical research worldwide is rapidly transforming through new digital strategies—especially in the field of rare diseases. Recent months …
Cutting-edge biomarker technologies are enabling faster, more accurate cancer diagnosis and tailored therapies, revolutionizing precision oncology.
A new multinational clinical trial marks a significant step in developing transformative gene therapies for rare inherited disorders.
Ionis Pharmaceuticals is driving progress in antisense technology, demonstrating meaningful advances in genetic disease treatment
Already a subscriber? Log in